Onpattro (patisiran) is a medication prescribed to adults that have polyneuropathy caused by hereditary ATTR (hATTR) amyloidosis.
hATTR amyloidosis is a result of a mutation in transthyretin (TTR) gene. As a result, the TTR protein misfolds, which inevitably results in misshapen proteins being deposited as amyloid throughout different tissues and organs in the body.
As these amyloid deposits build up, it can causes a variety of health conditions, the two most common being cardiomyopathy and neuropathy.
Onpattro works by preventing the growth of the TTR protein by breaking down mRNA. As new amyloid deposits are prevented, the body will begin breaking down old buildup, reducing symptoms of neuropathy.
Click here for additional side effects
Every three weeks
Before your infusion, it is important to drink plenty of water and come to your appointment hydrated. Additionally, you must alert us as soon as possible to any changes in your insurance to ensure that we are still an in-network provider for your infusion therapy.